To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial therapies. The primary efficacy endpoint will be the clinical response.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Enrollment
115
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.